Inflammatory Bowel Diseases Clinical Trial
Official title:
Corrona Inflammatory Bowel Disease (IBD) Registry
Verified date | March 2023 |
Source | CorEvitas |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Status | Enrolling by invitation |
Enrollment | 2287 |
Est. completion date | December 2100 |
Est. primary completion date | December 2100 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | ELIGIBILITY CRITERIA* To be eligible for enrollment into the Corrona IBD Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below. Inclusion Criteria: - At least 18 years of age or older. - Willing and able to provide written consent for participation in the IBD Registry. - Willing and able to provide Personally Identifiable Information (PII) which includes the following types of personal information at a minimum: full name, date of birth, sex, and home address zip code. - Diagnosis of one of the following by a gastroenterologist: 1. Crohn's disease 2. Ulcerative colitis - Prevalent users or new /incident users of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of UC or Crohn's disease. Exclusion Criteria: • Participating in or planning to participate in a clinical trial (Phase I - III) or a post-marketing study or registry (i.e. phase IV).? Eligible Medications Grouped by Drug Class ANTI-TNF AGENTS AND BIOSIMILARS - Adalimumab (HUMIRA), Adalimumab-atto (AMJEVITA), Certolizumab pegol (CIMZIA), Golimumab (SIMPONI), Infliximab (REMICADE), Infliximab-dyyb (INFLECTRA) INTEGRIN RECEPTOR ANTAGONISTS - Natalizumab (TYSABRI), Vedolizumab (ENTYVIO) INTERLEUKIN ANTAGONIST (IL-12 AND IL-23), Ustekinumab (STELARA), JAK INHIBITOR - Tofacitinib (XELJANZ) SPHINGSOSINE-1-PHOSPHATE RECEPTOR (S1PR) - Ozanimod (ZEPOSIA) ? Once clinical trial participation has ended, a patient is permitted to enroll in the registry if they satisfy the eligibility requirements. * These criteria are subject to change with the needs of the registry at the sole discretion of the Sponsor (Corrona). |
Country | Name | City | State |
---|---|---|---|
United States | Corrona, LLC | Waltham | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
CorEvitas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | IBD epidemiology, presentation, natural history, management, and outcomes | The major clinical outcomes include an assessment of the epidemiology of Inflammatory Bowel Disease; to better understand the presentation, natural history, management and outcomes. | Time Frame: A minimum of 10 years from last patient enrolled | |
Secondary | Disease burden: Harvey-Bradshaw Index | [Time Frame: every 6 months for 10 years] | ||
Secondary | Disease burden: Fistula History | [Time Frame: every 6 months for 10 years] | ||
Secondary | Disease burden: Disease Location and Behavior | [Time Frame: every 6 months for 10 years] | ||
Secondary | Percentage of patients with history of comorbidities | [Time Frame: time frame: at registry enrollment] | ||
Secondary | Physician reported: Pouchitis | [Time Frame: time frame: every 6 months for 10 years] | ||
Secondary | Physician reported: Simple Clinical Colitis Activity Index (SCCAI) | [Time Frame: time frame: every 6 months for 10 years] | ||
Secondary | Physician reported: Mayo Severity Index | [Time Frame: time frame: every 6 months for 10 years] | ||
Secondary | Physician reported: IBD related extraintestinal manifestations | [Time Frame: time frame: every 6 months for 10 years] | ||
Secondary | Patient reported: Patient reported: Work productivity and Activity Impairment (WPAI) | [Time Frame: time frame: every 6 months for 10 years] | ||
Secondary | Patient reported: PROMIS | [Time Frame: time frame: every 6 months for 10 years] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |